Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(0.79)
# 3,901
Out of 4,960 analysts
319
Total ratings
22.86%
Success rate
-28.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics | Upgrades: Buy | $35 | $14.90 | +134.90% | 14 | Aug 15, 2025 | |
| VTVT vTv Therapeutics | Reiterates: Buy | $36 | $16.00 | +125.00% | 2 | Aug 13, 2025 | |
| FEMY Femasys | Maintains: Buy | $12 → $8 | $0.57 | +1,301.05% | 25 | Aug 11, 2025 | |
| CNTX Context Therapeutics | Maintains: Buy | $5 → $4 | $0.89 | +347.93% | 12 | Aug 7, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $10 → $9 | $2.19 | +310.12% | 2 | Jul 22, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $6 → $27 | $11.32 | +138.62% | 2 | Jul 10, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $40 → $20 | $2.93 | +582.59% | 10 | Jul 7, 2025 | |
| NXTC NextCure | Reiterates: Buy | $36 | $5.12 | +603.13% | 9 | Jul 1, 2025 | |
| ACLX Arcellx | Reiterates: Buy | $115 | $71.28 | +61.34% | 13 | Jun 16, 2025 | |
| ARTV Artiva Biotherapeutics | Assumes: Buy | $12 | $2.88 | +316.67% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 | $4.52 | +453.10% | 18 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $38 | $20.22 | +87.93% | 10 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.76 | +420.83% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $3.58 | +207.26% | 11 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $0.70 | +4,485.18% | 14 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $10.26 | +2,629.04% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.83 | +337.16% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.74 | +589.66% | 13 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $3.78 | +693.65% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.36 | +1,297.06% | 12 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.37 | +659.49% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $6.50 | +2,709.38% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.78 | +800.32% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.46 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $10.53 | +127.92% | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $58 | $38.80 | +49.48% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.13 | +1,492.92% | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.74 | - | 15 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $12.43 | +205.71% | 18 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $2.30 | +1,337.91% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.51 | - | 1 | Apr 25, 2024 |
MiNK Therapeutics
Aug 15, 2025
Upgrades: Buy
Price Target: $35
Current: $14.90
Upside: +134.90%
vTv Therapeutics
Aug 13, 2025
Reiterates: Buy
Price Target: $36
Current: $16.00
Upside: +125.00%
Femasys
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.57
Upside: +1,301.05%
Context Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.89
Upside: +347.93%
SAB Biotherapeutics
Jul 22, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $2.19
Upside: +310.12%
RAPT Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $6 → $27
Current: $11.32
Upside: +138.62%
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $2.93
Upside: +582.59%
NextCure
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $5.12
Upside: +603.13%
Arcellx
Jun 16, 2025
Reiterates: Buy
Price Target: $115
Current: $71.28
Upside: +61.34%
Artiva Biotherapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $12
Current: $2.88
Upside: +316.67%
Jun 4, 2025
Upgrades: Buy
Price Target: $25
Current: $4.52
Upside: +453.10%
Jun 4, 2025
Upgrades: Buy
Price Target: $22 → $38
Current: $20.22
Upside: +87.93%
Apr 28, 2025
Reiterates: Buy
Price Target: $30
Current: $5.76
Upside: +420.83%
Apr 24, 2025
Reiterates: Buy
Price Target: $11
Current: $3.58
Upside: +207.26%
Apr 22, 2025
Reiterates: Buy
Price Target: $32
Current: $0.70
Upside: +4,485.18%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $10.26
Upside: +2,629.04%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $1.83
Upside: +337.16%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.74
Upside: +589.66%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $3.78
Upside: +693.65%
Mar 28, 2025
Reiterates: Buy
Price Target: $19
Current: $1.36
Upside: +1,297.06%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.37
Upside: +659.49%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $6.50
Upside: +2,709.38%
Mar 26, 2025
Reiterates: Buy
Price Target: $7
Current: $0.78
Upside: +800.32%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Feb 26, 2025
Upgrades: Buy
Price Target: $24
Current: $10.53
Upside: +127.92%
Feb 24, 2025
Reiterates: Buy
Price Target: $58
Current: $38.80
Upside: +49.48%
Feb 3, 2025
Reiterates: Buy
Price Target: $18
Current: $1.13
Upside: +1,492.92%
Jan 14, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.74
Upside: -
Jan 14, 2025
Reiterates: Buy
Price Target: $38
Current: $12.43
Upside: +205.71%
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $2.30
Upside: +1,337.91%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.51
Upside: -